Item 1.01 Entry into a Material Definitive Agreement
As previously reported on a Current Report on Form 8-K filed with the Securities
and Exchange Commission on May 13, 2022, Bio Lab Naturals, Inc., a Delaware
corporation (the "Company"), entered into a Share Exchange Agreement (the
"Agreement") with Limitless X, Inc., a Nevada corporation ("LimitlessX"), and
its 11 shareholders (the "Shareholders") on May 11, 2022.
On August 2, 2022, the Company, LimitlessX, and the Shareholders entered into
Amendment No. 1 to the Share Exchange Agreement (the "Amendment"). Pursuant to
the Amendment, the parties agreed to remove and delete Article III, Sections 3.5
and 3.6, and those sections shall have no further force or effect whatsoever.
Such sections prohibited the Company, for a period of 12 months following the
closing of the Agreement, from selling any equity securities at a price less
than $0.40 per share or from effecting any reverse stock split, subject to
certain exceptions. The Company shall no longer be restricted by these
prohibitions pursuant to the Amendment.
A copy of the Amendment is attached hereto as Exhibit 10.1
1
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Description
10.1 Amendment No. 1 to Share Exchange Agreement, dated August 2, 2022
104 Cover Page Interactive Data File (formatted as an Inline XBRL document)
2
© Edgar Online, source Glimpses